
Coherus BioSciences CHRS
€ 1.38
-5.03%
Quartalsbericht 2025-Q3
hinzugefügt 06.11.2025
Coherus BioSciences Betriebsaufwand 2011-2026 | CHRS
Betriebsaufwand Jährlich Coherus BioSciences
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 231 M | 204 M | 234 M | 306 M | 249 M | 95.8 M | 38.7 M | 40.4 M | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 306 M | 38.7 M | 175 M |
Betriebsaufwand Vierteljährlich Coherus BioSciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 79.8 M | 70.4 M | 75.3 M | 78.8 M | 59.8 M | 55.9 M | 53.7 M | 60.5 M | 57 M | 44.9 M | 42 M | 46.5 M | 56.6 M | 58 M | 72.6 M | 74.3 M | 78.2 M | 76.8 M | 76.7 M | 62.4 M | 78.4 M | 65.8 M | 42.6 M | 33.1 M | 22.5 M | 22.9 M | 17.4 M | 11.7 M | 7.29 M | 9.79 M | 9.94 M | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 79.8 M | 7.29 M | 51.7 M |
Betriebsaufwand anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M | ||
|
AgeX Therapeutics
AGE
|
10.1 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
209 M | - | - | $ 1.01 B | ||
|
Alterity Therapeutics Limited
ATHE
|
16.7 M | $ 3.59 | 1.99 % | $ 8.64 B | ||
|
Arrowhead Pharmaceuticals
ARWR
|
731 M | $ 66.05 | 2.3 % | $ 8.83 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | ||
|
Autolus Therapeutics plc
AUTL
|
145 M | $ 1.52 | -16.3 % | $ 388 M | ||
|
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | ||
|
Biogen
BIIB
|
5.39 B | $ 184.48 | -1.67 % | $ 26.9 B | ||
|
AVROBIO
AVRO
|
71.7 M | - | 1083.1 % | $ 745 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | ||
|
BioNTech SE
BNTX
|
512 M | $ 102.17 | 2.32 % | $ 27.2 B | ||
|
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M | ||
|
AstraZeneca PLC
AZN
|
17.6 B | $ 93.52 | -1.2 % | $ 96.9 B | ||
|
Can-Fite BioPharma Ltd.
CANF
|
14 M | $ 4.25 | 1.67 % | $ 9.25 B | ||
|
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B | ||
|
Bellicum Pharmaceuticals
BLCM
|
28.5 M | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
152 M | - | -7.31 % | $ 87 M | ||
|
Bristol-Myers Squibb Company
BMY
|
12.2 B | $ 55.71 | -0.28 % | $ 113 B | ||
|
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - | ||
|
Ascendis Pharma A/S
ASND
|
338 M | $ 207.49 | 2.22 % | $ 5 B | ||
|
Codiak BioSciences
CDAK
|
92.5 M | - | -55.98 % | $ 2.15 M | ||
|
ARCA biopharma
ABIO
|
88.1 M | - | 1052.0 % | $ 415 M | ||
|
Cerevel Therapeutics Holdings
CERE
|
447 M | - | - | $ 7.29 B | ||
|
Acasti Pharma
ACST
|
24.4 M | - | 4.01 % | $ 150 M | ||
|
Zai Lab Limited
ZLAB
|
212 M | $ 18.37 | -0.97 % | $ 18.2 B | ||
|
Catalyst Biosciences
CBIO
|
176 M | $ 10.84 | 0.46 % | $ 714 M | ||
|
Caladrius Biosciences
CLBS
|
23.4 M | - | -16.75 % | $ 25.8 M | ||
|
Celldex Therapeutics
CLDX
|
58.1 M | $ 25.59 | -6.54 % | $ 1.65 M | ||
|
Cellectis S.A.
CLLS
|
109 M | $ 4.22 | -4.2 % | $ 116 M | ||
|
Clearside Biomedical
CLSD
|
33.1 M | - | - | $ 25.3 M | ||
|
Chimerix
CMRX
|
93.4 M | - | - | $ 756 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
141 M | - | -15.15 % | $ 60.3 M | ||
|
Corcept Therapeutics Incorporated
CORT
|
189 M | $ 37.35 | -0.4 % | $ 3.86 B | ||
|
Catalyst Pharmaceuticals
CPRX
|
190 M | $ 23.18 | 2.02 % | $ 2.75 B | ||
|
AIkido Pharma
AIKI
|
29.7 M | - | 1.93 % | $ 17.4 M | ||
|
Albireo Pharma
ALBO
|
163 M | - | -0.23 % | $ 916 M | ||
|
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | ||
|
Acer Therapeutics
ACER
|
24.6 M | - | 2.71 % | $ 14 M | ||
|
Alpine Immune Sciences
ALPN
|
88.2 M | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
65.4 M | - | 4.14 % | $ 49.1 M | ||
|
Crinetics Pharmaceuticals
CRNX
|
340 M | $ 55.11 | 3.49 % | $ 4.45 B | ||
|
CRISPR Therapeutics AG
CRSP
|
504 M | $ 55.17 | 2.47 % | $ 4.65 B | ||
|
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M | ||
|
Zentalis Pharmaceuticals
ZNTL
|
300 M | $ 3.53 | -5.75 % | $ 231 M | ||
|
Ampio Pharmaceuticals
AMPE
|
9.57 M | - | -11.43 % | $ 502 K | ||
|
Amphastar Pharmaceuticals
AMPH
|
168 M | $ 29.43 | 6.09 % | $ 1.43 B |